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Abstract 
Background: Melanoma is a serious malignant cancer with a low survival rate. On a global scale, breast cancer is 
the most frequent malignancy and leading cause of cancer death in women. Long non-coding RNAs (lncRNAs) can 
be used effectively as regulators and biomarkers in several cancers. Accordingly, the treatment plans of cancer 
patients could be made easier because of this. It has been reported that lncRNAs can play regulatory functions in 
various cancers, including melanoma. It is necessary to improve melanoma research programs and health policies, 
including in poor countries, around the world.  
Objective: The function of lncRNA lung cancer associated transcript 1 (LUCAT1) in melanoma has still not been 
identified. In the present study, large-scale screening for the differentially expressed lncRNAs was performed by 
lncRNAs microarray and finding the relationship between LUCAT1 and stemness marker.  
Methods and materials: LncRNA LUCAT1 expression was assessed in cancer tissues by in situ hybridization. 
Sphere-formation assay and colony-formation assay were used to detect cell self-renewal and proliferation, 
respectively. RNA pull-down and luciferase reporter assays were used to identify LUCAT1. 
Results: Silenced LUCAT1 can reduce cell growth, migration and invasion, and promote cell apoptosis, of 
melanoma. Conversely, over-expressed LUCAT1 can promote the progression of melanoma cells. 
Conclusions: The expression of LUCAT1 in melanoma cells was detected via quantitative real-time polymerase 
chain reaction (qRT-PCR) assay. We found that lncRNA LUCAT1 was significantly upregulated in melanoma cells. 
Then, we further searched the role of lncRNA LUCAT1 in melanoma. [Ethiop. J. Health Dev. 2020; 34(4):293-300] 
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Introduction 
Despite steady progress in research related to cancer and 
melanoma, there are still many challenges. Improving 
research in this area will allow us to lessen the threat 
caused by melanoma and decrease the mortality rate. 
Research should focus on early detection, tumor cell 
dormancy and therapy. A detailed understanding of 
tumor signaling causing melanoma will help us to 
develop specific therapies and drugs, and decrease the 
burden of tumors. The sole purpose of this research 
work is to use biotechnology as tool to diagnose highly 
prevalent diseases to benefit human health and society 
as a whole.  
 
Acting as an aggressive skin cancer, melanoma is 
responsible for the loss of many lives (1). The 
occurrence of melanoma has been increasing and 
accounts for nearly 5% of all skin cancers (2). Because 
of the metastasis character of melanoma, the five-year 
survival rate is just 13% (3-4). Even though there have 
been significant improvements in the diagnosis of 
melanoma, the same cannot be said of treatment. 
Therefore, it is vital to conduct research to search for the 
inner mechanisms underlying melanoma.  
 
Long non-coding RNAs (lncRNAs) have been reported 
to play crucial regulatory roles in the progression of 
various human diseases (5). In the case of cancer, this 
includes cell growth, apoptosis, migration and invasion 
(6). For example, LINC00880 (long intergenic non-
protein coding RNA 880) can act as an oncogene in 
spinal cord ependymoma to activate cell growth and 
progress epithelial mesenchymal transition (EMT) by 
modulating the expression of calcium voltage-gated 
channel auxiliary subunit gamma 5 (CACNG5), a 
protein coding gene (7). And LINC00673 can promote 
the cell growth and migration of non-small cell lung 
cancer (NSCLC) cells by regulating MiR-150-5p 
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expression (8). Lung cancer associated transcript 1 
(LUCAT1) has been identified as acting as an oncogene 
in many cancers, such as NSCLC, esophageal squamous 
cell carcinoma, and clear cell renal cell carcinoma (9-
11). However, the function of lncRNA LUCAT1 in 
melanoma has still not been identified. This study aims 
to explore its function in relation to melanoma. 
 
LncRNAs, which are a type of RNA, contain more than 
200 nucleotide sequences; these sequences do not have 
the ability to encode a protein or translate into protein. 
As noted above, lncRNAs have the ability to participate 
in cell proliferation, differentiation and apoptosis. 
Accordingly, they are capable of controlling various 
biological pathways. Research has shown that lncRNAs 
have the capability of upregulating and downregulating 
the progression of tumor cells. Studies have shown that 
LL22NC03-N64E9.1 is a class of RNA which is 
responsible for the progression and metastasis effect of 
cancerous cells on the lung’s wall. As with previous 
examples, LL22NC03-N64E9.1 has a positive effect 
on the Wnt/B catenin signaling pathway, where 
interaction between catenin B and protein first starts the 
pathway and then it consistently activates signaling 
Junction. This pathway is different from the LL22NC03 
in terms of the location of the cancer and the type of 
cancerous cell. Basically, LINC00210 is responsible for 
malignant phenotype of liver cancer.  
 
Breast cancer is one type of cancer that can be initiated 
by the effect of lncRNA-Hh. LncRNA-Hh activates the 
hedgehog signaling pathway, which is involved in 
transmitting information to embryonic cells required for 
proper cell differentiation to promote the progression of 
breast cancer cells. Research is ongoing to understand 
the mechanism of LUCAT1 in breast cancer 
progression.  
 
Recent studies have focused on some of the prognostic 
factors that have positive effects on the progression of 
carcinoma cells. LncRNA LUCAT1 is one type of 
adverse prognostic factor that is responsible for the 
progression of carcinoma cells. It is able to initiate 
hepatocellular carcinoma, acting like a signaling 
molecule. In this signaling pathway, LUCAT1 inhibits 
the function of Annexin A2 to initiate the tumorigenesis.  
 
Research suggests that functions of LUCAT1 are linked 
with p21 and p57 expression, which are the cyclin-
dependent kinase inhibitors (Kip2), (Waf1/Cip1/Sdi1) 
and (Kip1). LUCAT1 is epigenetically repressed p21 
and p57 expression. Due to this terminate p21 and p57 
expression system, LUCAT1 is able to take control of 
the development and cell proliferation of NSCLC.  
 
Cell viability can be affected by the elimination of 
lncRNA LUCAT1. The function of LUCAT1 is 
dependent on the micro RNA signaling pathway. For 
example, by regulating the miR-612 pathway, LUCAT1 
can initiate ovarian cancer and is responsible for the 
progression of cancerous cells. As noted above, the 
function of LUCAT1 in breast cancer is not well 
identified. LncRNA can function like micro RNA 
sponges, whereas competitive endogenous RNA 
(ceRNA) can also serve like micro RNA and lncRNA. 
These three class of RNA show a similar type of 
function and all are responsible for the tumorigenesis of 
hepatocellular carcinoma. LncRNA MIR31HG has a 
negative effect on carcinoma progression, modulating 
ST7L expression and inhibiting cancer cells’ 
proliferation. This gene produces a lncRNA that acts as 
a host gene for MiR31 and sponge MiRNA575. In 
addition, the degradation of lung adenocarcinoma can be 
expected when NEAT1 (a class of lncRNA) is 
successfully engaged with mir-193a-3p. This kind of 
engagement site can be observed between LUCAT1 and 
micro-RNA5702. Research reveals that LUCAT1 is not 
closely linked with the progression of triple negative 
breast cancer (TNBC). But it does helps to develop 
tumorigenesis of TNBC by interacting with MiR5702. 
In the future, this junction (lncRNA–MiR5702) could be 
targeted as a break point for cancer to develop new 
therapeutic drugs.  
 
LncRNA LUCAT1 is directly linked with clear cell renal 
cell carcinoma. LUCAT1 is the most common 
provoking gene that has a clear relationship with the 
development of esophageal cell carcinoma. In addition, 
LUCAT1 is associated with multiple myeloma, which is 
a class of tumor in plasma cells. In this type of 
tumorigenesis, the amount of transforming growth 
factor B (TGF-B) in the plasma is always above its 
normal level. TGF-B is one of the essential factors in the 
formation of bone that is damaged by multiple myeloma, 
and plays a crucial role on the proliferation of myeloma 
cells because of their activity in the site of the cancer. 
They simply increase lytic bone disease and block the 
body’s own immune system to protect against cancer 
cells, thereby initiating angiogenesis. If the TGB-B 
signaling pathway is blocked for any reason, it will slow 
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down the progression of the myeloma. LUCAT1, with 
the help of miR-200c, can control osteosarcoma 
formation. As said earlier, LUCAT1 acts as a stimulant 
of the AKT pathway, which can regulate the progression 
of carcinoma. Research is still ongoing on the effect of 
the LUCAT1 gene on breast cancer progression, so the 
mechanism of the gene in breast cancer proliferation is 
still unclear. Sometimes, LUCAT1 can act like an 
inhibitory molecule in breast cancer development. With 
the help of MiR-7-5P, the LUCAT1 gene exhibits 
increased levels of SOX2 adsorption and this increases 
the response to SOX2 sensitivity, a transcription factor 
essential for maintaining self-renewal, and will inhibit 
the progression of breast cancer.  
 
As discussed above, LUCAT1 regulates the 
differentiation and progression of clear cell renal cell 
carcinoma. Regulation is through the ATK signaling 
pathway. When the chemokine CXCL2 is released from 
the carcinoma cell then over-expression of the LUCAT1 
gene occurs. Over-expression of the LUCAT1 gene will 
enhance the proliferation rate of carcinoma cells and 
arrest all nearby cells in the G1 phase of the cell cycle. In 
the present study, we explore the function of LUCAT1 
in melanoma. 
 
Materials and methods 
Cell culture: Human melanoma cell samples (A2058, 
M21, A375, A-875) and human keratinocytes (HaCaT), 
available from ATCC (Rockville, Maryland, USA), 
were preserved in Dulbecco’s Modified Eagle Medium 
(DMEM), which is used for cultivation of cell cultures 
(Invitrogen, Carlsbad, CA, USA). Cell culture was 
achieved with the application of 10% fetal bovine serum 
(FBS; Invitrogen) and 1% Pen/Strep mixture under 
standard condition of 5% CO2 and 37oC, with DMEM 
replaced every three days. 
 
RNA extraction and quantitative real-time PCR (qRT-
PCR): Total RNAs from culture cell samples were 
extracted by use of Invitrogen TRIzol reagent, a 
monophasic solution of phenol and guanidine 
isothiocyanate, for the reverse transcription in light of 
the manual (Thermo Fisher, Waltham, MA, USA). 
qPCR was conducted by employing SYBR green 
Supermix (Thermo Fisher). The change in gene 
expression was calculated with the comparative change-
in-cycle method (ΔΔCt), normalized to GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) or U6 
expression. 
 
Plasmid transfection: The synthesized short hairpin 
RNAs for LUCAT1 and negative control (NC) shRNAs 
were procured from Genepharma Company (Shanghai, 
China). In addition, pcDNA3.1/LUCAT1 and NC 
pcDNA3.1 vector (both Genepharma Company) were 
used for over-expressing LUCAT1. pcDNA 3.1 contains 
an ampicillin antibiotic resistance site, regions of the 
CMV promoter and SV40 promoter site. A target opens 
reading frame without any stop codon. pUC region 
along with F1 region. The pUC and the F1 region is the 
origin of replication site. There are few restricted sites 
present such as Nhe I, BahmH 1, Hind III and Kpn I. 
The 48 hour of plasmid transfection in the A2058 cell 
line was implemented in line with the instruction of kit 
Lipofectamine 2000 (Invitrogen). 
 
Colony formation: A2058 cell lines at the log phase of 
growth were harvested and resuspended, then seeded 
into the 6-well, plated with a density of 500 cells per 
well. Cells were cultured for two weeks. After washing 
in modified Dulbecco’s phosphate-buffered saline 
(PBS), cells were fixed using 4% paraformaldehyde, and 
then processed with 0.1% crystal violet staining 
solution. The clones were counted visually. 
 
EdU staining assay: Using the 5-ethynyl-20-
deoxyuridine (EdU) incorporation assay kit, cell 
proliferation was assessed by EdU staining assay, as per 
the user guide (Ribobio, Guangzhou, China). After 48 
hours of transfection, each well of 96 well plates were 
filled with EdU medium diluent. Three hours later, cells 
were fixed and permeabilized for nuclear detection with 
DAPI (4’,6-diamidino-2-phenylindole) dye. Stained 
cells were assayed under fluorescence microscope 
(Nikon, Tokyo, Japan). 
 
Transwell migration and invasion assay: Migration 
assay for A2058 cells was performed with transwell 
chambers (Corning, Corning, NY, USA) of 8mm pore 
size. The lower chamber was added with DMEM 
containing 10% FBS. DMEM is the most broadly 
suitable medium for many adherent cell phenotypes 
among defined media for cell and tissue culture. DMEM 
is a modification of Basal Medium Eagle (BME) that 
contained 1,000 mg/l of glucose and was first reported 
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for culturing embryonic mouse cells. A further alteration 
with 4,500 mg/l glucose has proved to be optimal for the 
cultivation of certain cell types. A2058 cells in serum-
free DMEM were put into the upper chamber. Chambers 
were cultivated at 37°C in 5% CO2 for 48 hours. Then 
cells in the upper chamber were removed with cotton 
swabs, while those on the bottom surface were counted 
using 0.1% crystal violet dye and microscope. Invasion 
assay for A2058 cells was performed using transwell 
chambers coated with Matrigel (Clontech, Madison, WI, 
USA). 
 
Flow cytometry apoptosis assay: After 48 hours of 
transfection, A2058 cells (2 × 105) were reaped and 
rinsed in pre-cooled PBS. Apoptotic cells were 
monitored using an Annexin V-FITC/PI apoptosis kit 
(Life Technologies, Carlsbad, CA, USA). Annexin V 
and propidium iodide (PI) were both purchased from BD 
Biosciences (Franklin Lakes, NJ, USA) and added to the 
binding buffer. After 15 minutes of treatment, cells were 
assayed applying the FACSCalibur flow cytometer (BD 
Biosciences). 
 
TUNEL staining assay: Terminal deoxynucleotidyl-
transferase (TdT) mediated dUTP nick-end labeling 
(TUNEL) staining assay was applied to measure the cell 
apoptosis level of A2058. Based on the protocol 
supplied with the in situ cell death detection kit (Roche, 
Basel, Switzerland), cultured A2058 cells were fixed 
using 4% paraformaldehyde and permeabilized with 
0.1% Triton-X100. Following incubation in the TUNEL 
reaction mixture, cell nuclei were stained with DAPI 
after one hour. Samples were visualized using 
fluorescence microscopes.  
 
TdT is an enzyme which tries to repair double stranded 
breaks. It searches for a break in the DNA strand and 
incorporates itself there and converts the nick end of the 
DNA break to a blunt end. Once the blunt end is made, 
the TdT will start adding dUTP in the terminal region of 
the DNA. dUTP is added until it forms a loop-like 
structure to make them close. What makes this assay 
particularly interesting is that TdT does not require any 
template strand to add nucleotide sequence to it, as it is 
a template-independent addition system. This means 
that dUTP will be incorporated depending on the 
amount of apoptosis going on inside the cell, as cell 
apoptosis leads to the breakdown of DNA. Hence, we 
can correlate apoptosis with the amount of TdT acting 
inside the cell. The dUTP are tagged with either 
enzymes or fluorescent tags. These modified dUTP 
when added will give a coloration when the assay will 
be running, giving an idea about cell apoptosis or cell 
death. This is because the dUTP will be added only to 
the broken DNA that are found in apoptotic cells.  
 
Statistical analysis: All experiments included more than 
two independent repeats, and results were all 
represented with the standard deviation (SD). GraphPad 
PRISM 6 (GraphPad, San Diego, CA, USA) was 
employed for data analysis with one-way ANOVA or 
Student’s t-test. All statistical significances were 
specified as p-values below 0.05. 
 
Results 
LUCAT1 was highly expressed in melanoma cells: It is 
reported that LUCAT1 is aberrantly upregulated in 
NSCLC, esophageal squamous cell carcinoma and clear 
cell renal cell carcinoma (9-11). We searched for the 
expression of LUCAT1 in melanoma cells. QRT-PCR 
assay found that LUCAT1 was highly expressed in 
melanoma cells (A2058, M21, A375 and A-875) 
compared with normal human keratinocytes (HaCaT) 
(see Figure 1A). Meanwhile, inhibition and over-
expression efficiency of LUCAT1 were also searched in 
A2058 cells via qRT-PCR assay (see Figures 1B and 
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Figure 1: LUCAT1 was highly expressed in melanoma cells and their assay 
A: Expression of lncRNA LUCAT1 was assessed via qRT-PCR assay in normal human keratinocytes (HaCaT) 
and melanoma cells (A2058, M21, A375 and A-875); B: Inhibition efficiency of lncRNA LUCAT1 in A2058 cells 
was tested via qRT-PCR assay; C: Over-expression efficiency of lncRNA LUCAT1 in A2058 cells was tested via 
qRT-PCR assay. 
 
Over-expressed LUCAT1 can promote the progression 
of melanoma cells: The function of over-expressed 
LUCAT1 in melanoma cells was also identified. Colony 
formation and EdU assay found that the cell growth was 
further elevated by over-expressed LUCAT1 (see 
Figures 2A and 2B). Also, gain of function LUCAT1 
also promoted cell migration and invasion via transwell 
assay (see Figure 2C). In short, over-expressed 
LUCAT1 can promote the progression of melanoma 
cells. 
  
Figure 2: Over-expressed LUCAT1 and progression of melanoma cells  
A and B: Colony formation assay and EdU assay investigated the cell proliferation of A2058 cells when LUCAT1 
was over-expressed; C. Transwell assay searched the cell migration and invasion when LUCAT1 was over-
expressed in A2058 cells. 
 
 





LUCAT1 depletion could promote cell apoptosis in 
melanoma: Furthermore, we identified the regulation of 
LUCAT1 on melanoma cell apoptosis. According to the 
results of flow cytometry analysis and TUNEL, we 
found that cell apoptosis was significantly elevated via 
silenced LUCAT1 (see Figure 3B). Accordingly, 
LUCAT1 depletion can promote cell apoptosis in 
melanoma. 
  
Figure 3: LUCAT1 depletion and apoptosis in melanoma 
 
Silenced LUCAT1 can reduce the cell growth, 
migration and invasion of melanoma: We further 
identified the function of LUCAT1 in melanoma cells. 
Functional assays such as colony formation assay, EdU 
assay and transwell assay were conducted to search the 
cell proliferation, migration and invasion of A2058 
cells. Colony formation assay and EdU assay found that 
cell growth was significantly inhibited by LUCAT1 
depletion, as the number of colonies and positive stained 
cells were both decreased by LUCAT1 depletion (see 
Figures 4A and 4B). Transwell assay detected that cell 
migration and invasion were reduced by LUCAT1 
depletion (see Figure 4C). In brief, silenced LUCAT1 
can reduce the cell growth, migration and invasion of 
melanoma. 
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Figure 4: Silenced LUCAT1 and  cell growth, migration and invasion of melanoma 
A and B: Cell proliferation of A2058 cells was tested via colony formation assay and EdU assay when LUCAT1 




In our study, we detected the expression of lncRNA 
LUCAT1 in melanoma cells using qRT-PCR assay. We 
found that LUCAT1 was significantly upregulated in 
melanoma cells. Then, we further searched the role of 
LUCAT1 in melanoma. Previous studies have 
investigated the role of LUCAT1, finding that it can 
promote the progression of many cancers. For instance, 
it can activate cell growth of NSCLC and aggravate its 
progression by reducing the expression of p21 and p57 
(11). Also, LUCAT1 can inhibit esophageal squamous 
cell carcinoma cell apoptosis by regulating the 
expression of DNMT1 (10). In addition, LUCAT1 can 
enhance the cell invasion and growth of clear cell renal 
cell carcinoma (9).  
 
Colony formation assay and EdU assay found cell 
proliferation was significantly decreased by silenced 
LUCAT1 and activated by over-expressed LUCAT1. 
And cell migration and invasion were found inhibited 
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via LUCAT1 depletion and elevated by over-expressed 
LUCAT1 through transwell assay. Meanwhile, flow 
cytometry analysis and TUNEL assay found cell 
apoptosis was upregulated by silenced LUCAT1.  
 
In the present study, we firstly identified the oncogene 
role of LUCAT1 in melanoma cells for providing more 
possible mechanism study in melanoma. The major 
findings of our study indicate that LUCAT1 is a 
potential therapeutic target and molecular biomarker for 
melanoma. LUCAT1 can address through the 
AKT/GSK-3β signaling pathway melanoma cell 
proliferation and invasion. Another necessary factor is 
that chemokine CXCL2 (macrophage inflammatory 
protein-2) is also responsible for the over-expression of 
LUCAT1 (9-11).  
 
Conclusions 
The study has attempted to portray the role of LUCAT1 
in the development of melanoma. This work will further 
strengthen the research done in the field of cancer, offer 
a deeper insight into the causative and genetic mutations 
causing cancer, and will also enhance the advancement 
of melanoma research by providing information 
regarding the genes responsible for causing melanoma.  
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